New Horizons in the Treatment of Corneal Endothelial Dysfunction

Rocha-de-Lossada, Carlos, Rachwani-Anil, Rahul, Borroni, Davide ORCID: 0000-0001-6952-5647, Sanchez-Gonzalez, Jose-Maria, Esteves-Marques, Raquel, Soler-Ferrandez, Fernando-Luis, Gegundez-Fernandez, Jose-Antonio, Romano, Vito ORCID: 0000-0002-5148-7643, Livny, Eitan and Rodriguez Calvo-de-Mora, Marina
(2021) New Horizons in the Treatment of Corneal Endothelial Dysfunction. JOURNAL OF OPHTHALMOLOGY, 2021. 6644114-.

[img] Text
New Horizons in the Treatment of Corneal Endothelial Dysfunction.pdf - Published version

Download (2MB) | Preview


The treatment of corneal endothelial dysfunction has experienced a revolutionary change in the past decades with the emergence of endothelial keratoplasty techniques: descemet stripping automated endothelial keratoplasty (DSAEK) and descemet membrane endothelial keratoplasty (DMEK). Recently, new treatments such as cultivated endothelial cell therapy, Rho-kinase inhibitors (ROCK inhibitors), bioengineered grafts, and gene therapy have been described. These techniques represent new lines of treatment for endothelial dysfunction. Their advantages are to help address the shortage of quality endothelial tissue, decrease the complications associated with tissue rejection, and reduce the burden of postoperative care following transplantation. Although further randomized clinical trials are required to validate these findings and prove the long-term efficacy of the treatments, the positive outcomes in preliminary clinical studies are a stepping stone to a promising future. Our aim is to review the latest available alternatives and advancements to endothelial corneal transplant.

Item Type: Article
Divisions: Faculty of Health and Life Sciences
Faculty of Health and Life Sciences > Institute of Life Courses and Medical Sciences
Depositing User: Symplectic Admin
Date Deposited: 23 Dec 2021 15:25
Last Modified: 18 Jan 2023 21:18
DOI: 10.1155/2021/6644114
Related URLs: